Title:
COMBINATION DRUG INCLUDING TLR7 AGONIST
Document Type and Number:
WIPO Patent Application WO/2019/124500
Kind Code:
A1
Abstract:
The present invention provides an effector memory T cell inducer or MHC class I inducer that is to be used in combination with an immune checkpoint inhibitor, includes a TLR7 agonist, and is for treating or preventing cancer. The present invention also provides a cancer treatment agent or prevention agent that is to be used in combination with an immune checkpoint inhibitor and includes a TLR7 agonist.
More Like This:
Inventors:
OTA YOSUKE (JP)
OTSUBO TAKESHI (JP)
OTSUBO TAKESHI (JP)
Application Number:
PCT/JP2018/047011
Publication Date:
June 27, 2019
Filing Date:
December 20, 2018
Export Citation:
Assignee:
SUMITOMO DAINIPPON PHARMA CO LTD (JP)
International Classes:
A61K45/00; A61K31/505; A61K39/395; A61P31/00; A61P35/00; A61P37/04; A61P43/00
Domestic Patent References:
| WO2017079431A1 | 2017-05-11 | |||
| WO2008114817A1 | 2008-09-25 | |||
| WO2016179475A1 | 2016-11-10 | |||
| WO2013172479A1 | 2013-11-21 | |||
| WO1998001448A1 | 1998-01-15 | |||
| WO1999028321A1 | 1999-06-10 | |||
| WO2002085905A1 | 2002-10-31 | |||
| WO2008114008A1 | 2008-09-25 | |||
| WO2008114819A1 | 2008-09-25 | |||
| WO2008114817A1 | 2008-09-25 | |||
| WO2008114006A1 | 2008-09-25 | |||
| WO2010018131A1 | 2010-02-18 | |||
| WO2010018134A1 | 2010-02-18 | |||
| WO2008101867A1 | 2008-08-28 | |||
| WO2010018133A1 | 2010-02-18 | |||
| WO2009005687A1 | 2009-01-08 | |||
| WO2000012487A1 | 2000-03-09 | |||
| WO2010133885A1 | 2010-11-25 | |||
| WO2012136834A1 | 2012-10-11 | |||
| WO2010048520A1 | 2010-04-29 | |||
| WO2008135791A1 | 2008-11-13 | |||
| WO2007030777A2 | 2007-03-15 | |||
| WO2010077613A1 | 2010-07-08 |
Foreign References:
| JP2015520729A | 2015-07-23 | |||
| JP2017523244A | 2017-08-17 | |||
| US20110077263A1 | 2011-03-31 | |||
| US4689338A | 1987-08-25 | |||
| US4698348A | 1987-10-06 |
Other References:
SINGH, MANISHA ET AL.: "Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation", THE JOURNAL OF IMMUNOLOGY, vol. 193, September 2014 (2014-09-01), pages 4722 - 4731, XP055290072
RAUSCH, JOHANNA ET AL.: "Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 87, no. 3, September 2017 (2017-09-01), pages 300 - 306, XP085171161
NISHII, NAOTO ET AL.: "Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy", ONCOTARGET, vol. 9, no. 17, 2 March 2018 (2018-03-02), pages 13301 - 13312, XP055620401
NAT REV CANCER, vol. 12, 2012, pages 252 - 64
NAT REV DRUG DISCOV., vol. 14, no. 8, August 2015 (2015-08-01), pages 561 - 8
J IMMUNOL., vol. 193, no. 9, 1 November 2014 (2014-11-01), pages 4722 - 31
MEDCHEMCOMM, vol. 2, 2011, pages 185
NAT REV DRUG DISCOV., vol. 12, 2013, pages 130 - 146
NIKKEI MEDICAL CANCER REVIEW, vol. 9, 2014
NAT REV IMMUNOL., vol. 14, 2014, pages 559 - 69
RAUSCH, JOHANNA ET AL.: "Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization", JOURNAL OF DERMATOLOGICAL SCIENCE, vol. 87, no. 3, September 2017 (2017-09-01), pages 300 - 306, XP085171161
NISHII, NAOTO ET AL.: "Systemic administration of a TLR7 agonist attenuates regulatory T cells by dendritic cell modification and overcomes resistance to PD-L1 blockade therapy", ONCOTARGET, vol. 9, no. 17, 2 March 2018 (2018-03-02), pages 13301 - 13312, XP055620401
NAT REV CANCER, vol. 12, 2012, pages 252 - 64
NAT REV DRUG DISCOV., vol. 14, no. 8, August 2015 (2015-08-01), pages 561 - 8
J IMMUNOL., vol. 193, no. 9, 1 November 2014 (2014-11-01), pages 4722 - 31
MEDCHEMCOMM, vol. 2, 2011, pages 185
NAT REV DRUG DISCOV., vol. 12, 2013, pages 130 - 146
NIKKEI MEDICAL CANCER REVIEW, vol. 9, 2014
NAT REV IMMUNOL., vol. 14, 2014, pages 559 - 69
Attorney, Agent or Firm:
YAMAO, Norihito et al. (JP)
Download PDF: